Ruesch_Drip1_100920v3

View web version
This promotional, non-CME program is sponsored by Pfizer Inc.

Thursday, April 22 • 7:00 PM ET

Overview of the efficacy, safety profile, and dosing
for a first-line advanced RCC combination regimen

This is a live virtual event with an opportunity for Q&A featuring Amit Mehta, MD as he discusses a first-line combination regimen for patients with advanced RCC.

Attend this event to have greater insight on the following:

Renal cell carcinoma (RCC) in the United States
Mechanisms of action
Warnings & Precautions
Clinical data

Dosing and administration
Patient monitoring checklist
NCCN^® recommendation
Summary

Presented By:

Amit Mehta, MD
GU Medical Oncologist
Premiere Hematology & Oncology
Cary, North Carolina

This promotional, non-CME program is sponsored by: